ABSTRACT
2 cotransporter 1 and the K 1 -Cl 2 cotransporter 2 (KCC2). This results in delayed gamma-aminobutyric acid switch and higher susceptibility to seizures, which endures up to adulthood. Chromatin immunoprecipitation experiments reveal increased binding of the repressor factor RE1-silencing transcription (also known as neuronrestrictive silencer factor) to position 509 of the KCC2 promoter that leads to downregulation of KCC2 transcription in prenatally exposed offspring. Interleukin-1 receptor type I knockout mice, which display braked immune response and no brain cytokine elevation upon maternal immune activation, do not display KCC2/Na 1 -K 1 -2Cl 2 cotransporter 1 imbalance when implanted in a wild-type dam and prenatally exposed. Notably, pretreatment of pregnant dams with magnesium sulfate is sufficient to prevent the early inflammatory state and the delay in excitatory-to-inhibitory switch associated to maternal immune activation. CONCLUSIONS: We provide evidence that maternal immune activation hits a key neurodevelopmental process, the excitatory-to-inhibitory gamma-aminobutyric acid switch; defects in this switch have been unequivocally linked to diseases such as autism spectrum disorder or epilepsy. These data open the avenue for a safe pharmacological treatment that may prevent the neurodevelopmental defects caused by prenatal immune activation in a specific pregnancy time window. Disruption of correct neurodevelopmental trajectories by maternal immune activation (MIA) is a critical factor in the development of neurological and neuropsychiatric disorders (1-3), especially when maternal infections synergize with a susceptible genetic background or when the prenatal event is followed by postnatal risk factors that act as "second hits" (3,4) .
In recent years, the consequences of maternal infections on offspring brain have been explored using mouse models based on prenatal exposure to immune stimuli (5-9). The immunogens most commonly used in rodent models have been lipopolysaccharide, a component of the cell wall of gram-negative bacteria that binds to toll-like receptor 4 and mimics bacterial infection, or polyinosinic:polycytidylic acid (PolyI:C), a doublestranded, synthetic RNA that binds to toll-like receptor 3 like viral nucleic acid. Injection of either immunogen initiates a signaling cascade that leads to the production of inflammatory mediators, such as chemokines, cytokines, and complement proteins (10).
Consistent with epidemiological data, preclinical studies in these models have shown a wide spectrum of long-term behavioral changes, including impaired sensorimotor gating (prepulse inhibition) (8, 11, 12) , increased anxiety-like behavior (13), cognitive deficits (12, 14) , and altered exploratory behavior (6,12). The phenotypic abnormalities in offspring are frequently accompanied by brain alterations, although with a high degree of variability depending on the specific immune activation paradigm (7, 15, 16) . Injecting the immunogen at different time points during gestation leads to different neuropathological features (6), gene expression profiles (7), and behavioral abnormalities in offspring (6).
Although epidemiological and preclinical evidence indicate that intrauterine exposures elicit enduring effects on offspring, 
